SCHEMBL14255477

SCHEMBL14255477

CCC(=O)NN1CCN(C)CC1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.55
CA2 P00918 2/20 0.55
CA9 Q16790 2/20 0.55
HTT P42858 2/20 0.45
ALDH1A1 P00352 1/20 0.45
TP53 P04637 1/20 0.45
CA1 P00915 1/20 0.45
KMT2A Q03164 2/20 0.44
LMNA P02545 1/20 0.44
MAPK1 P28482 1/20 0.44
CYP2D6 P10635 1/20 0.43
GAA P10253 1/20 0.43
MEN1 O00255 1/20 0.41
HDAC8 Q9BY41 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
LIPE Q05469 1/20 0.40
HTR1A P08908 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13030073 0.88 CA12 (0.42) CA12CA2CA9HTTALDH1A1
SCHEMBL14255478 0.83 CA12 (0.52) CA12CA2CA9HTTALDH1A1
SCHEMBL3875596 0.82 HTT (0.44) HTTALDH1A1LMNAMAPK1
SCHEMBL21834414 0.81 CA12 (0.53) CA12CA2CA9HTTALDH1A1
SCHEMBL5743453 0.81 CYP2D6 (0.44) CA12CA2CA9HTTKMT2A
SCHEMBL10667899 0.81 CA12 (0.53) CA12CA2CA9HTTALDH1A1
SCHEMBL30639268 0.80 GNAI3 (0.57) CA12CA2CA9HTTALDH1A1
SCHEMBL4591725 0.80 HTT (0.47) HTTALDH1A1TP53GAA
SCHEMBL18502886 0.78 CA12 (0.50) CA12CA2CA9HTTALDH1A1
SCHEMBL16353590 0.78 CA12 (0.50) CA12CA2CA9HTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3353168-A1 COMPOUNDS AND METHODS FOR INHIBITING JAK Dizal (Jiangsu) Pharmaceutical Co., Limited (CN) 2018-08-01 EP claimed
WO-2017050938-A1 COMPOUNDS AND METHODS FOR INHIBITING JAK ASTRAZENECA AB (SE) 2017-03-30 WO claimed
CN-119841829-A Compounds for the treatment of PI3K gamma mediated diseases and uses thereof 中国科学院合肥物质科学研究院 2025-04-18 CN disclosed
WO-2023226965-A1 ROCK INHIBITORS AND USES THEREOF DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2023-11-30 WO disclosed
EP-3956322-A1 JAK1 SELECTIVE KINASE INHIBITOR DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2022-02-23 EP disclosed
WO-2020211839-A1 JAK1 SELECTIVE KINASE INHIBITOR DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2020-10-22 WO disclosed
EP-2483249-B1 PYRIMIDINE DERIVATIVES AS PROTEIN TYROSINE KINASE 2 INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2015-12-23 EP disclosed
EP-2435411-B1 2,4-DIAMINOPYRIMIDINES FOR THE TREATMENT OF DISEASES CHARACTERISED BY EXCESSIVE OR ABNORMAL CELL PROLIFERATION BOEHRINGER INGELHEIM INT (DE) 2014-10-29 EP disclosed
US-8410126-B2 Pyrimidine inhibitors of PKTK2 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-04-02 US disclosed
US-7345040-B2 Reverse-turn mimetics and compositions and methods relating thereto MYRIAD GENETICS, INC. (US) 2008-03-18 US disclosed
US-7345040-B2 Reverse-turn mimetics and compositions and methods relating thereto MYRIAD GENETICS, INC. (US) 2008-03-18 US disclosed